Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glaxo Nicorette Ads Say NRTs Can Make Quitting "Suck Less"

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline hopes the tagline Nicorette "makes quitting suck less" for its nicotine-replacement therapy gum will connect emotionally with untapped elements of its potential market

You may also be interested in...

GSK Asks FDA To Mull Expansion Of NRT Indications

GlaxoSmithKline's Consumer Health division calls on FDA to consider expanding indications and use of over-the-counter nicotine replacement therapies to maximize the public health benefit

Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation

The tobacco control act prompts FDA to consider new indications - such as smoking reduction - for smoking cessation products, which could lead to new criteria for application approval

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts